PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

A Phase I, Multiple Dose Study of PF-04447943 in Healthy Elderly Volunteers

Phase 1

Terminated

Conditions: Healthy
Elderly

Interventions: Drug: PF-04447943
Drug: Placebo

First Posted Date: 2008-08-18

Last Posted Date: 2009-02-25

Lead Sponsor: Pfizer

Target Recruit Count: 10

Registration Number: NCT00736528

Locations: 🇺🇸
Pfizer Investigational Site, Gainesville, Florida, United States

Macugen Observational Study

Terminated

Conditions: Vascular Endothelial Growth Factor
Macular Degeneration

First Posted Date: 2008-08-15

Last Posted Date: 2011-08-29

Lead Sponsor: Pfizer

Target Recruit Count: 22

Registration Number: NCT00735943

Locations: 🇮🇳
Pfizer Investigational Site, Jaipur, Rajasthan, India

Trial Of AG-013736, Cisplatin, And Gemcitabine For Patients With Squamous Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Carcinoma, Non-Small-Cell Lung (NSCLC)

Interventions: Drug: AG-013736
Drug: gemcitabine
Drug: cisplatin

First Posted Date: 2008-08-15

Last Posted Date: 2013-01-03

Lead Sponsor: Pfizer

Target Recruit Count: 38

Registration Number: NCT00735904

Locations: 🇺🇦
Pfizer Investigational Site, Lviv, Ukraine

A 52-Week Open-Label Safety Study of PD 0332334 in Subjects With Generalized Anxiety Disorder (GAD)

Phase 3

Terminated

Conditions: Generalized Anxiety Disorder

First Posted Date: 2008-08-14

Last Posted Date: 2012-11-16

Lead Sponsor: Pfizer

Target Recruit Count: 468

Registration Number: NCT00735267

Locations: 🇺🇸
Pfizer Investigational Site, Waukesha, Wisconsin, United States

Follow-Up Study for Exubera

Completed

Conditions: Diabetes Mellitus

Interventions: Other: Randomized diabetes therapy
Drug: Exubera

First Posted Date: 2008-08-14

Last Posted Date: 2012-10-23

Lead Sponsor: Pfizer

Target Recruit Count: 7439

Registration Number: NCT00734591

Locations: 🇬🇧
Pfizer Investigational Site, Westbury, United Kingdom

Single Dose Escalation Study of PF-04360365 In Subjects With Mild To Moderate Alzheimer's Disease

Phase 1

Completed

Conditions: Alzheimer's Disease

Interventions: Biological: PF-04360365 1 mg/kg
Biological: PF-04360365 3 mg/kg
Biological: PF-04360365 5 mg/kg
Biological: PF-04360365 10 mg/kg

First Posted Date: 2008-08-13

Last Posted Date: 2009-07-28

Lead Sponsor: Pfizer

Target Recruit Count: 15

Registration Number: NCT00733642

Locations: 🇺🇸
Pfizer Investigational Site, Oakhurst, New Jersey, United States

Tanezumab in Osteoarthritis of the Knee

Phase 3

Completed

Conditions: Arthritis
Osteoarthritis

Interventions: Biological: Placebo
Biological: tanezumab

First Posted Date: 2008-08-13

Last Posted Date: 2021-03-22

Lead Sponsor: Pfizer

Target Recruit Count: 697

Registration Number: NCT00733902

Locations: 🇺🇸
Stamford Therapeutics Consortium, Stamford, Connecticut, United States
🇺🇸
Delray Research Associates, Delray Beach, Florida, United States
🇺🇸
University Clinical Research Incorporated, Pembroke Pines, Florida, United States

and more 77 locations

A Safety Study Of Sunitinib In Combination With Pemetrexed In Patients With Advanced Solid Malignancies

Phase 1

Completed

Conditions: Neoplasm, Malignant

Interventions: Drug: Sunitinib, Pemetrexed

First Posted Date: 2008-08-12

Last Posted Date: 2011-03-17

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT00732992

Locations: 🇯🇵
Pfizer Investigational Site, Osakasayama-shi, Osaka, Japan

An Investigation Of The Effects Of Food On The Absorption Of A Varenicline Controlled Release Formulation

Phase 1

Completed

Conditions: Pharmacokinetics
Bioavailability
Smoking Cessation

Interventions: Drug: Varenicline Tartrate Controlled Release

First Posted Date: 2008-08-11

Last Posted Date: 2010-01-11

Lead Sponsor: Pfizer

Target Recruit Count: 24

Registration Number: NCT00731562

Locations: 🇺🇸
Pfizer Investigational Site, Fargo, North Dakota, United States

A Single Dose Study Investigating The Elimination Of PD-0332334 In Patients Receiving Regular Hemodialysis

Phase 1

Completed

Conditions: Renal Dialysis
Pharmacokinetics

Interventions: Drug: PD-0332334

First Posted Date: 2008-08-08

Last Posted Date: 2010-02-17

Lead Sponsor: Pfizer

Target Recruit Count: 8

Registration Number: NCT00730145

Locations: 🇺🇸
Pfizer Investigational Site, Orlando, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy